Decapeptide corresponding to the C-terminal region of human kisspeptin (metastin residues 45–54)
Kisspeptin-10 — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
FDA compounding Category 2
- No approved drug product exists in Drugs@FDA.
- Kisspeptin-10 is on FDA's active Category 2 table for 503A compounding, added 29 September 2023. FDA's published concerns are immunogenicity risk for certain routes, peptide-related impurities and API characterisation, and no or limited safety information for the proposed routes.
- ClinicalTrials.gov lists registered human studies of kisspeptin. Registration is not approval.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built